Research Article
Lack of Clinical Relevance of ANA and ASMA Positivity in Patients with Liver Transplantation without a History of Autoimmune Diseases
Table 2
ANA positivity (≥1 : 80) according to different risk factors during the study period.
| | | ANA positivity (≥1 : 80) | Total number of patients | 0 | 6 | 12 |
| Gender | | | | | (i) Male | 76 | 59 (77.6) | 52 (68.4) | 47 (61.8) | (ii) Female | 38 | 32 (84.2) | 28 (73.7) | 28 (73.7) | | | 0.4 | 0.5 | 0.2 | Cause of transplantation | | | | | (i) HBV | 39 | 31 (79.5) | 26 (66.7) | 23 (59) | (ii) HCV | 57 | 45 (78.9) | 42 (73.7) | 39 (68.4) | (iii) Other | 18 | 15 (83.3) | 12 (66.7) | 13 (72.2) | | | 0.9 | 0.7 | 0.5 | HCC at the time of transplantation | | | | | (i) No | 74 | 58 (78.4) | 56 (75.7) | 50 (67.6) | (ii) Yes | 40 | 33 (82.5) | 24 (60) | 25 (62.5) | | | 0.6 | 0.08 | 0.6 | Early rejection | | | | | (i) No | 87 | 69 (79.3) | 59 (67.8) | 56 (64.4) | (ii) Yes | 27 | 22 (81.5) | 21 (77.8) | 19 (70.4) | | | 0.8 | 0.3 | 0.5 | Time from transplantation | | | | | (i) >3 months–1 year | 11 | 9 (81.8) | 7 (63.6) | 10 (90.9) | (ii) >1 year–5 years | 27 | 20 (74.1) | 19 (70.4) | 14 (51.8) | (iii) >5 years–10 years | 26 | 20 (76.9) | 19 (73.1) | 17 (65.4) | (iv) >10 years | 50 | 42 (84) | 35 (70) | 34 (68) | | | 0.7 | 0.9 | 0.1 | Age group at 0 | | | | | (i) ≤50 years | 15 | 11 (73.3) | 11 (73.3) | 12 (80) | (ii) >50–60 years | 34 | 27 (79.4) | 24 (70.6) | 20 (58.8) | (iii) >60 years | 65 | 53 (81.5) | 45 (69.2) | 43 (66.1) | | | 0.7 | 0.9 | 0.3 | Therapy at the time of the study (constant during the study) | | | | | (i) Cyclosporine | 32 | 28 (87.5) | 23 (71.9) | 21 (65.6) | (ii) FK | 55 | 46 (83.6) | 39 (70.9) | 38 (69.1) | (iii) Mycophenolate | 12 | 10 (83.3) | 7 (58.3) | 8 (66.7) | (iv) Everolimus | 15 | 7 (46.7) | 11 (73.3) | 8 (53.3) | | | 0.007 | 0.8 | 0.7 |
|
|